Robert Switz – Chairperson
In addition to Recombinetics, Mr. Switz is the Chairperson of the Board for Micron, Inc. (NASDAQ). He is also a Board Director for Marvell Technology Group (NASDAQ) and Gigamon, Inc. (NYSE), and is the former Chairman, President and CEO of ADC Telecommunications, Inc. Mr. Switz holds an MBA from the University of Bridgeport as well as a BS degree from Quinnipiac University.
Mitch Abrahamsen, PhD
Executive Vice President, Chief Commercial & Scientific Officer
Previously to joining Recombinetics, Dr. Abrahamsen was the Senior Vice President of Research and Development at Cobb-Vantress for Tyson Foods, Vice President of Research at Hill’s Pet Nutrition for Colgate-Palmolive, Vice President of Research and Development, Chief Scientific Officer of Pyxis Genomics, Inc, and a professor in the Department of Veterinary Pathobiology and Director of Graduate Studies, Molecular Veterinary Biosciences at University of Minnesota. Dr. Abrahamsen received a Bachelor’s degree in Biochemistry from the University of Minnesota and a PhD in Biochemistry from the University of Washington.
Scott C. Fahrenkrug, PhD
Founder of Recombinetics
Dr. Scott Fahrenkrug is an academic, inventor, entrepreneur and internationally recognized expert in food animal genetics, genomics, and advanced gene-editing technologies. His laboratories produce an ever-growing portfolio of intellectual property and world “firsts”, including the first development and application of site-specific endonucleases for editing animal genomes using TALENs and CRISPR/Cas9. Dr. Fahrenkrug has been instrumental in introducing the “Functional Genomics” paradigm, which maps, monitors and modifies food animal genetics to determine the “how, when, where and why” of gene function.Dr. Fahrenkrug earned a Ph.D. in molecular, cellular, development biology and genetics from the University of Minnesota where he became a professor in the Department of Animal Science, and a member of the University’s Center for Genome Engineering, Stem Cell Institute and Masonic Cancer Center.
Perry Hackett, PhD
Dr. Perry Hackett is a co-founder of Recombinetics and serves as Chair of its Scientific Advisory Board. He is a co-founder of gene therapy company, Discovery Genomics, where he previously served as Chief Scientific Officer and Chairman. He is also a professor and research scientist in the University of Minnesota’s department of Genetics, Cell Biology, and Development and co-founder of the Center for Genome Engineering. Hackett has a degree in Physics from Stanford University, a Ph.D. in Biophysics and Genetics from the University of Colorado, and did postdoctoral training at the Max Planck Institute for Cell Biology in Germany and at the University of California in San Francisco.
Hajas is the Chairman of the Board for FreshRealm. He previously served as the Chief Executive Officer and Chief Investment Officer of Telluride Asset Management, and was the President and Chief Operating Officer of Knight Trading Group. Prior to that he was Co-Managing Partner of Arbitrade and Deephaven Capital Management and Partner at O’Connor & Associates (including being a Managing Director of Swiss Bank Corp. and UBS). He holds multiple degrees from Loyola University of Chicago.
Jim Kilman, MA
Kilman is Chief Executive Officer of KielStrand Capital, a family office/merchant bank based in Scarborough, New York that makes and manages investments, provides advice and engages in philanthropic activities. Prior to forming KielStrand Capital in 2016, he retired as Vice Chairman of Investment Banking at Morgan Stanley. Kilman spent 32 years in the investment banking business, including senior roles at Goldman Sachs, ABN AMRO and PaineWebber. Kilman currently serves as Vice Chairman of the Board of alpha-En Corporation, a publicly-traded provider of lithium metal technology in Yonkers, NY and as Senior Advisor at Burford Capital Ltd, a London-listed global finance firm focused on law. He holds an M.A. and a B.A. in Economics from Yale University.
Wendell King, PhD
Dr. Wendell King is a seasoned leader in medical device development and manufacturing. He’s the CEO of King Consulting, served as Vice President and General Manager of the BioInterface Division of Medtronic, founded medical device company, Angeion and Gateway Alliance, LLC, an early-stage business incubator. King has numerous publications and has been granted more than 30 patents. He earned a Bachelor’s degree in engineering physics from the University of Minnesota, Institute of Technology, completed the Executive Business Administration Program at Dartmouth, Amos Tuck School of Business, and course work towards a PhD in polymer physics at the University of Akron, Polymer Institute.
Mark Kroll, PhD
Dr. Kroll was the former Chief Technology Officer at St. Jude Medical, Cardiac Rhythm Management Division. Dr. Kroll holds more patents for implantable devices than any inventor worldwide. Dr. Kroll is a Fellow of the American College of Cardiology and Adjunct Professor of Biomedical Engineering at the University of Minnesota and the California Polytechnical University, San Luis Obispo. Dr. Kroll received his B.S. degree in mathematics and an M.S. and Ph.D. in electrical engineering from the University of Minnesota and an MBA from the University of St. Thomas.